NCT07133997View on ClinicalTrials.gov

Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

November 26, 2025

Primary Completion Date

May 8, 2027

Study Completion Date

May 8, 2027

Conditions
Recurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic Leukemia
Interventions
DRUG

Asparaginase Erwinia chrysanthemi

Given IM

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

BIOLOGICAL

Blinatumomab

Given CIV

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration and biopsy

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow aspiration and biopsy

DRUG

Cyclophosphamide

Given cyclophosphamide

PROCEDURE

Echocardiography Test

Undergo ECHO

PROCEDURE

Lumbar Puncture

Undergo lumbar puncture

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

DRUG

Venetoclax

Given PO

DRUG

Vincristine

Given vincristine

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER